|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO007857195 |
003 |
DE-627 |
005 |
20230605130953.0 |
007 |
cr uuu---uuuuu |
008 |
210902s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO007857195
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)TCTR20210714006
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)Nil Known
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Corticosteroid Nasal Irrigation as Early Treatment of Olfactory Dysfunction in COVID-19: A prospective randomized controlled trial
|b Corticosteroid Nasal Irrigation as Early Treatment of Olfactory Dysfunction in COVID-19: A prospective randomized controlled trial
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 14-07-2021, Last updated: 2023-06-05
|
650 |
|
4 |
|a Medical Condition: The eligible COVID-19 patients who admit at Ramathibodi Hospitel, Ramathibodi Hospital and Ramathibodi Chakri Naruebodindra Hospital with new onset smell loss who capable to perform nasal irrigation themselves. COVID-19, Anosmia, Hyposmia, Budesonide;COVID-19, Anosmia, Hyposmia, Budesonide
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 29. Mai
|
773 |
1 |
8 |
|g year:2023
|g day:29
|g month:05
|
856 |
4 |
0 |
|u https://www.thaiclinicaltrials.org/show/TCTR20210714006
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 29
|c 05
|